The immunosuppressive agent, mycophenolic
|
|
- Luke Skinner
- 5 years ago
- Views:
Transcription
1 IMMUNOSUPPRESSION Effect of Mycophenolate Mofetil Therapy on Lymphocyte Activation in Heart Transplant Recipients Guenter Weigel, MD, a Andrea Griesmacher, MD, a Ali Karimi, b Andreas O. Zuckermann, MD, a Michael Grimm, MD, a and Mathias M. Mueller, MD b Background: Mycophenolic acid is reported to provide effective immunosuppression by inhibiting inosine monophosphate dehydrogenase. In an attempt to monitor the effects of therapy with mycophenolate mofetil, we measured the expression of the activation markers CD25, CD38, CD69 and HLA-DR on lymphocytes of patients after heart transplantation. Methods: Thirty-six patients enrolled in the study were randomly assigned to one of two groups. Patients in the control group (n 15) received cyclosporine, azathioprine and prednisone. Patients in the study group (n 21) were switched from azathioprine to mycophenolate mofetil (MMF) 3 months after heart transplantation. The expressions of the activation markers CD25, CD38, CD69 and HLA-DR on B cells, T cells and natural killer (NK) cells in peripheral blood were determined by flow cytometry. Results: In patients treated with MMF a significant reduction of the B-cell count was observed in comparison to a healthy control group and patients under therapy with azathioprine. The decline of B cells in the MMF group started 3 months after onset of therapy and, after 1 year, was nearly halved. In addition, the percentages of CD38- positive B cells, activated T cells (CD4 /CD25, CD8 /CD38 ) and HLA-DR expressing NK cells were reduced during therapy with MMF. Conclusions: Our studies have shown administration of MMF to be associated with a reduction of B lymphocytes and a downregulation of activation markers on B cells. In contrast to in vitro findings, our data indicate that the immunosuppressive effect of MMF in vivo is exhibited mainly on B cells. J Heart Lung Transplant 2002;21: The immunosuppressive agent, mycophenolic acid (MPA), an active metabolite of the pro-drug mycophenolate mofetil (MMF), shows specific activity in lymphocytes where the target enzyme, inosine monophosphate dehydrogenase (IMPDH), is blocked and the production of GTP is inhibited. From the a Department of Cardiothoracic Surgery, University of Vienna Medical School, Vienna, Austria; and b Ludwig Boltzmann Institute at the Department of Laboratory Diagnostics, Kaiser Franz Josef Hospital, Vienna, Austria. Submitted November 8, 2001; revised January 5, 2002; accepted March 14, Supported by the EU Project BMH4-CT Reprint requests: Dr. Andrea Griesmacher, Ludwig Boltzmann Institute at the Department of Laboratory Diagnostics, Kaiser Franz Josef Hospital, Kundratstrasse 3, A-1100 Vienna, Austria. Telephone: Fax: andrea.griesmacher@kfj.magwien.gv.at Copyright 2002 by the International Society for Heart and Lung Transplantation /02/$ see front matter PII S (02)
2 The Journal of Heart and Lung Transplantation Weigel et al Volume 21, Number 10 TABLE I Patient characteristics Mycophenolate Mofetil Azathioprine Patients (n) Age (mean SD) Gender (M/F) 20 /1 14 /1 Diagnosis Ischemic cardiomyopathy 9 7 Dilative cardiomyopathy 10 8 Other 2 0 Donor age SD (years; mean SD) Ischemic time SD (minutes; mean SD) Although most cell lines are capable of recycling purine nucleotides via the salvage pathway, lymphocytes rely predominantly on the de novo synthesis so that treatment with MPA leads to the inhibition of DNA synthesis. In addition to their role in DNA synthesis guanine nucleotides are required for the transfer of sugar structures to cell-surface glycoproteins. 1 The selective inhibition of lymphocyte proliferation by MPA has been demonstrated in allostimulated mice injected with tritium-labeled thymidine. 2,3 Gummert et al showed that MPA inhibits mitogen-stimulated lymphocyte proliferation as well as the expression of cell-surface cytokine receptors in rat whole blood. 4 However, the published data on the in vitro effects of MPA on the expression of cell-surface antigens are controversial. 5 7 Despite the valuable information these studies have provided, the in vivo mechanism of action of MPA is poorly understood and its effect on surface markers that characterize lymphocyte activation is less clear. In the pathogenesis of graft rejection CD4 T-cell activation plays an important role. 8 Upon activation these cells proliferate, express interleukin-2 (IL-2) receptors on their surface and secrete cytokines including IL-2. They can be identified in the graft, where they regulate cytotoxic T cells, B cells and macrophages, which causes destruction of the graft via cell- and/or antibody-mediated lysis of target cells. The locally infiltrating lymphocytes are recruited from other lymphoid tissues and presumed to circulate through the peripheral blood, thereby reflecting the local immune response within the graft. CD25 (IL-2 receptor chain) is expressed in the early phase after T-cell activation and the clonal proliferation of activated T cells depends on the expression of this receptor. CD38 and CD69 are not expressed on resting lymphocytes, but they do appear upon activation on T cells, natural killer (NK) cells and B cells. 9,10 In recent years, the application of flow cytometry has progressed rapidly, and there have been attempts to correlate post-operative immunophenotypic monitoring of peripheral blood mononuclear leukocytes with rejection episodes in transplant recipients. In addition, immunophenotyping analyses of blood have been applied to the diagnosis of viral infection and cyclosporine toxicity in an attempt to distinguish these processes from rejection. 11,12 The purpose of this in vivo study on patients after heart transplantation was to assess in peripheral blood by flow cytometry whether MMF immunomodulation affects the expression of the early activation markers CD25, CD38 and CD69 as well as that of HLA-DR on lymphocytes, which may contribute to the immunosuppressive efficacy of MPA in vivo. PATIENTS AND METHODS Patients Thirty-six patients were enrolled in this study after they underwent orthotopic heart transplantation. All patients provided informed consent for the switch from azathioprine to mycophenolate mofetil. Demographic data for both groups are shown in Table I. There were no differences between groups in recipient age, gender, diagnosis for transplantation, donor age and ischemic time. Randomization was performed so that every odd-numbered patient was included in the study group (mycophenolate mofetil) and every even-numbered patient received the control medication (azathioprine). Initially, all patients received the same immunosuppressive therapy, which consisted of anti-thymocyte globulin as induction therapy over a period of 7 days and maintenance therapy that consisted of cyclosporine,
3 1076 Weigel et al. The Journal of Heart and Lung Transplantation October 2002 azathioprine (2 mg/kg per day) and prednisone (1 mg/kg per day, which was then decreased to a maintenance dose of 0.15 to 0.2 mg/kg per day) from the first day up to 3 months after cardiac transplantation. Cyclosporine target levels, as measured with an Abbott monoclonal fluorescence polarization immunoassay, varied between 150 and 250 ng/ml during Months 2 to 6, and between 100 and 150 ng/ml thereafter. After 3 months, patients were separated into groups according to the randomization scheme. The control group (n 15) received cyclosporine, azathioprine and prednisone. Patients in the study group (n 21) were switched from azathioprine to mycophenolate mofetil (1 g twice daily). When leukopenia occurred (white blood cell count 4 G/liter), therapy with azathioprine or mycophenolate mofetil was stopped until the leukocyte count recovered. Sample Collection Venipuncture was performed on a biweekly basis during the first 3 months after the switch from azathioprine to mycophenolate mofetil. Thereafter, blood specimens were collected in the outpatient clinic every second month for follow-up. Blood samples of patients that were drawn within 6 days before the diagnosis of infection or rejection were excluded retrospectively. Blood samples from 15 age-matched healthy subjects (mean age 53 9 years) served as controls. Flow Cytometric Analysis Analyses of leukocyte surface antigens were performed within 8 hours after venipuncture. All antibodies used were monoclonal mouse anti-human antibodies and fluorescently labeled with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or peridinin-chlorophyll (Per-CP). They were purchased from Becton Dickinson (USA). One hundred microliters of whole blood was incubated with the appropriate antibody combination (10 l of each antibody). After 15-minute incubation, the red blood cells were lysed with a lysing solution (Becton Dickinson) and the remaining cells were washed three times using phosphate-buffered saline (PBS; CellWash, Becton Dickinson, San Jose, CA). At least 10,000 leukocytes were analyzed on a FACSscan flow cytometer (Becton Dickinson). Results are expressed as percentages of positive cells (mean SE). Lymphocytes positive for CD19 were identified as B cells, cells co-staining for CD3 and CD4 as helper T cells, cells co-staining for CD3 and CD8 as suppressor/cytotoxic T cells and those staining positive for CD16 and CD56 as natural killer cells (NK cells). Statistical Analysis Values are expressed as mean SE. Wilcoxon s signed rank test was used and p 0.05 was considered statistically significant. RESULTS Clinical Outcome Survival in both groups was 100% at 1 year. Thereafter, there were 3 deaths in the mycophenolate mofetil group (pulmonary embolism 1, graft arteriosclerosis 2) and 1 death in the azathioprine group (graft arteriosclerosis). Freedom from rejection was 81% at 3 months, 81% at 12 months and 76% at 36 months in the mycophenolate mofetil group; freedom from infection was 86% at 3 months, 62% at 12 months and 57% at 36 months. In the azathioprine group, freedom from rejection was 80% at 3 months, 67% at 12 months and 67% at 36 months; freedom from infection was 67% at 3 months, 40% at 12 months and 27% at 36 months. The differences in rejection and infection rates between the two study groups did not reach statistical significance. Expression Patterns In patients given long-term treatment ( 11 months) with MMF a significant reduction in B-cell count was observed in comparison to healthy control patients and patients under therapy with azathioprine (Table II). The decline of B-cells in the MMF group started 3 months after onset of therapy (Figure 1), and after 1 year was nearly halved. No significant differences in T-cell percentages were found between healthy control subjects and patients under therapy with either MMF or azathioprine (AZA) (Table II). In contrast, a slight percentage increase in CD3-positive T cells (p 0.038) was observed in the MMF group when compared with patients under therapy with AZA (Table II). From the activation markers investigated on B cells, the percentage of CD38-positive B-cells was significantly lower in patients treated with MMF when compared with healthy subjects or patients treated with AZA (Table II). In contrast, AZA therapy led to a statistically significant reduction of both CD25- and CD69-positive B-cells compared with patients in the control group (Table II).
4 The Journal of Heart and Lung Transplantation Weigel et al Volume 21, Number 10 TABLE II Expression of surface antigens on peripheral blood leukocytes Healthy Subjects Azathioprine MMF Leukocytes/ l 8, , , Lymphocytes/ l 2, , , CD * CD CD4/CD CD8/CD CD16/CD CD19/CD CD4/CD CD8/CD * * CD16/CD CD19/CD * CD4/CD CD8/CD CD16/CD CD19/CD CD3/HLA-DR CD4/HLA-DR CD8/HLA-DR CD16/HLA-DR Data expressed as percentage of total lymphocytes (CD3, CD19) or positive T-cells (CD4, CD8), B-cells (CD19) or NK-cells (CD16) and measured in patients treated with azathioprine or mycophenolate mofetil (MMF) for 11 months. *p 0.05 and p 0.01 (significant differences compared with a healthy control group). p 0.05 and p 0.01 (significant differences compared with heart transplant recipients receiving azathioprine). Values represent mean SE. The expression of HLA-DR on B cells in both groups ( % of total B-cells in the MMF group vs % in the AZA group) was not significantly different, whereas both MMF and AZA dramatically reduced the percentages of activated (CD16/CD25 double-positive) NK cells. FIGURE 1 Time course of B-lymphocytes. Line graphs showing percentages of B-cells in heart-transplant recipients treated with azathioprine (filled circles/dashed lines) or MMF (filled squares/solid lines) # p 0.05 and ## p 0.01 (significant differences vs patients treated with azathioprine).
5 1078 Weigel et al. The Journal of Heart and Lung Transplantation October 2002 Although the T-cell count increased slightly in the MMF group, expression levels of activation markers CD25, CD38 and CD69 on T cells were not statistically significantly altered when compared with healthy controls (Table II). In contrast, treatment with azathioprine did not prevent upregulation of CD25 and CD38 on CD4 T cells and CD8 T cells, respectively (Table II). A significant increase in HLA-DR expression on T cells was seen in both (MMF and AZA) groups. Treatment with MMF upregulated HLA-DR on all CD3-positive cells, whereas AZA affected the CD4- and CD8-positive T-cell subsets only (Table II). Therefore, when comparing HLA-DR/CD3 doublepositive cells between the two groups, a statistically significantly higher percentage of HLA-DR positive CD3 cells was found in the MMF group (Table II). A similar effect was observed for HLA-DR expression on NK cells in the AZA group (Table II), which led to a significant reduction of HLA-DR positive cells in the MMF group (p 0.007) (Table II). DISCUSSION Until now, very few reports have dealt with the activation of lymphocytes after organ transplantation. Most were in vitro studies wherein isolated white blood cells were incubated with one or more immunosuppressive agents for rather short periods. 5,13 15 The aim of this study was to monitor the expression of activation markers such as CD69, CD25 and CD38 as well as HLA-DR. B-, T- and NK-cells were analyzed in heart-transplant patients receiving triple therapy consisting of CyA, corticoids and azathioprine or MMF. Thereby, we demonstrated that MMF therapy not only reduces the percentage of total B cells but also induces a tendentious reduction of B-cell activation markers. Azathioprine decreased the expression of the activation marker CD69 on B-cells, but did not influence the percentage of B-lymphocytes. The decrease of CD25 expression (except on CD4-positive cells) seen in both groups might be partially attributable to calcineurin inhibition, because all patients received CyA. In contrast to MMF, treatment with azathioprine did not prevent the upregulation of CD25 on CD4-positive and of CD38 on CD8-positive T lymphocytes. In both groups, an upregulation of HLA-DR was seen, an effect usually observed after organ transplantation. 16 Although neither the triple therapy including MMF nor the combination therapy with azathioprine could suppress the enhanced expression of HLA-DR on T-lymphocytes in patients after heart transplantation, the percentages of HLA-DR positive T-lymphocytes were lower in the azathioprine group. In contrast to azathioprine, MMF prevented HLA-DR expression on NK cells. In MMF-treated patients, the increase of ready-toactivate HLA-DR positive T lymphocytes seems to have been compensated by a decrease in total and CD38-positive B cells as well as in activated CD4 and CD8 T cells. Azathioprine led to a reduction of the T-cell count as well as to a reduction of B-cells expressing CD69. When comparing the effects of MMF and azathioprine, it is obvious that MPA was more effective in reducing the frequencies of CD38- positive B-cells, CD25-positive CD4 T cells and CD38-positive CD8 T-cells. In contrast to Eugui et al, 5 who reported that in vitro the expression of the IL-2 receptor (CD25) on mitogen-stimulated human T lymphocytes is not affected by MPA, we found a significant reduction of this activation marker in vivo. This is in accordance with the observations made by Thomson et al, 7 who reported an MPA dose-dependent inhibition of CD25 expression on human lymphocytes after alloantigen stimulation. The effects of MMF on CD38 expression seem to be of special importance because this surface marker is predominantly expressed on hematopoietic cells, where its expression correlates with differentiation and proliferation. Kilmartin et al 17 showed a reduction of CD69-positive CD4 T cells in patients with active uveitis treated with MMF. We did not observe this effect in our patients, which is probably due to the fact that blood samples of patients that were drawn within 6 days before the diagnosis of infection or rejection were excluded retrospectively. The expression of CD69 on B-lymphocytes in heart-transplant recipients treated with MMF increased by 50% in comparison to patients treated with azathioprine. GTP-binding proteins (G proteins) have been shown to be involved in the expression of activation markers such as CD Recently, it was shown that MMF therapy leads to an increase in intracellular GTP levels in red blood cells. 19 Whether a transient or permanent increase of GTP in B cells can explain the enhanced CD69 expression requires further investigation. In summary, we have shown, for the first time, that MPA not only leads to a reduction in the percentage of B-cells but also to a downregulation of activation markers in patients after heart transplantation. The immunosuppressive effect of MPA in clinical transplantation may therefore be related not only to inhibition of lymphocyte proliferation but also to the inhibition of cell-surface antigen expression, which is in line with the findings of Gummert et al 4 in a rat
6 The Journal of Heart and Lung Transplantation Weigel et al Volume 21, Number 10 model. Although in vitro studies have shown that MPA also affects the function of T cells, 15 our in vivo data provide evidence that, in patients given long-term treatment with MMF, the immunosuppressive effect is exhibited mainly on B-cells. Russell et al 20 provided evidence that inhibition of the humoral response after transplantation must be considered for controlling chronic allograft vasculopathy, and our findings support a potential role of MMF for preventing graft sclerosis. REFERENCES 1. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 1993;685: Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994;26: Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996;10: Gummert JF, Barten MJ, Sherwood SW, van Gelder T, Morris RE. Pharmacodynamics of immunosuppression by mycophenolic acid: Inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharm Exp Ther 1999;291: Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyteselective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33: Weaver JL, Pine PS, Aszalos A. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. Immunopharmacol Immunotoxicol 1991;13: Thomson AW, Woo J, Yao GZ, Todo S, Starzl TE, Zeevi A. Effects of combined administration of FK 506 and the purine synthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transplant Immunol 1993; 1: Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338: Jackson DG, Bell JI. Isolation of a cdna encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol 1990;144: Testi R, Philips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989;143: Garner RJ, Springgate C, Hoyt T. Immune monitoring of blood in heart transplant recipients: application of flow cytometry. Sem Diagn Path 1989;6: Kocher AA, Dockal M, Weigel G, et al. Immune monitoring in cardiac transplant recipients. Transplant Proc 1997;29: Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS Transplant Proc 1991;23(suppl 2): Grailer A, Nichols J, Hullet D, Sollinger HW, Burlingham WJ. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and FK506. Transplant Proc 1991;23: Heinschink A, Raab M, Daxecker H, Griesmacher A, Mueller MM. In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes. Clin Chim Acta 2000;300: Waaga AM, Gasser M, Kist-van Holthe JE, et al. Regulatory functions of self-restricted MHC class II allopeptide Th2 clones in vivo. J Clin Invest 2001;107: Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD. CD69 expression on peripheral CD4 T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci 2001;42: Lippert E, Jacques Y, Hermouet S. Positive regulation of human T cell activation by Gi2 proteins and interleukin-8. J Leukoc Biol 2000;67: Weigel G, Griesmacher A, Zuckermann AO, Laufer G, Mueller MM. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001;69: Russell PS, Chase CM, Colvin RB. Alloantibody- and T cellmediated immunity in the pathogenesis of transplant arteriosclerosis. Transplantation 1997;64:
Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationProton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium
Proton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium S. Kofler, C. Wolf, Z. Sisic, J. Behr, M. Vogeser, M. Shipkova, B. Meiser, G. Steinbeck, B. Reichart,
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationLong-term efficacy and safety of conversion to tacrolimus in heart. transplant recipients with ongoing or recurrent acute cellular.
Long-term efficacy and safety of conversion to tacrolimus in heart transplant recipients with ongoing or recurrent acute cellular rejection Blanka Skalická, Ivan Málek, Miloš Kubánek, Jevgenija Vymětalová,
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationCHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
More informationPediatric Pharmacotherapy
Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 4 Number 8, August 1998 Mycophenolate mofetil: Use in pediatrics Beth Ann Fullmer, R.Ph.,
More informationTransplantation Immunology
Transplantation Immunology Mitchell S. Cairo, MD Professor of Pediatrics, Medicine and Pathology Chief, Division, Pediatric Hematology & Blood & Marrow Transplantation Children s Hospital New York Presbyterian
More informationTransplantation Immunology
Transplantation Immunology MHC Restricted Allograft Rejection Mitchell S. Cairo, MD Professor of Pediatrics, Medicine and Pathology Chief, Division, Pediatric Hematology & Blood & Marrow Transplantation
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 July 14.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 17 20. The Effects of FK 506 on Renal Function After Liver Transplantation J. McCauley, J.
More informationOrganic dust-induced interleukin-12 production activates T- and natural killer cells
Eur Respir J 22; 2: 686 69 DOI:.1183/931936.2.222 Printed in UK all rights reserved Copyright #ERS Journals Ltd 22 European Respiratory Journal ISSN 93-1936 Organic dust-induced interleukin-12 production
More informationAutoimmunity & Transplantation. Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Autoimmunity & Transplantation Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Recognize
More informationBasis and Clinical Applications of Interferon
Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance
More informationManipulation of the Immune Response - Immunomodulation -
Manipulation of the Immune Response - Immunomodulation - Janeway s Immunobiology, 9 th ed., 2017. Ivana Novak Nakir Immune system Immune system make components, cells and organs that act together to defend
More informationMycophenolate Mofetil
Mycophenolate Mofetil Cynthia L. Chen, MD The Permanente Medical Group, Northern California Diablo Service Area February 17, 2018 January 23, 2018 2011 Kaiser Foundation Health Plan, Inc. For internal
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationBetter than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct
Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus
More informationFIT Board Review Corner March 2016
FIT Board Review Corner March 2016 Welcome to the FIT Board Review Corner, prepared by Sarah Spriet, DO, and Tammy Peng, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationNATURAL KILLER T CELLS EBOOK
08 April, 2018 NATURAL KILLER T CELLS EBOOK Document Filetype: PDF 90.41 KB 0 NATURAL KILLER T CELLS EBOOK Natural killer T cells (NK T cells) are a type of lymphocyte, or white blood cell. Natural killer
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1991 December ; 23(6): 2777 2779. Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic Liver Transplant
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationCHAPTER 18: Immune System
CHAPTER 18: Immune System 1. What are four characteristics of the specific immune system? a. b. c. d. 2. List the two main types of defense mechanisms and briefly describe features of each. 3. Give examples
More informationImmunology - Lecture 2 Adaptive Immune System 1
Immunology - Lecture 2 Adaptive Immune System 1 Book chapters: Molecules of the Adaptive Immunity 6 Adaptive Cells and Organs 7 Generation of Immune Diversity Lymphocyte Antigen Receptors - 8 CD markers
More informationSoluble Fas and Fas-Ligand Plasma Levels in Heart. or Tacrolimus
SCRIPTA MEDICA (BRNO) 79 (3): 163 168, July 2006 Soluble Fas and Fas-Ligand Plasma Levels in Heart Transplant Recipients Treated with Neoral or Tacrolimus Hökl J. 1, Černý J. 1, Ondrášek J. 1, Bedáňová
More informationSEVENTH EDITION CHAPTER
Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationThe Adaptive Immune Response. T-cells
The Adaptive Immune Response T-cells T Lymphocytes T lymphocytes develop from precursors in the thymus. Mature T cells are found in the blood, where they constitute 60% to 70% of lymphocytes, and in T-cell
More informationT cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
More informationHistocompatibility antigens
Histocompatibility antigens Tuesday 09 November 2010 Telegraph UK Livers grown in the laboratory could eventually solve organ transplant shortage. Made-to-measure organs for transplantation are a step
More informationSupplemental Table I.
Supplemental Table I Male / Mean ± SEM n Mean ± SEM n Body weight, g 29.2±0.4 17 29.7±0.5 17 Total cholesterol, mg/dl 534.0±30.8 17 561.6±26.1 17 HDL-cholesterol, mg/dl 9.6±0.8 17 10.1±0.7 17 Triglycerides,
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/23854 holds various files of this Leiden University dissertation. Author: Marel, Sander van der Title: Gene and cell therapy based treatment strategies
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationLecture 4. T lymphocytes
Lecture 4 T lymphocytes Objectives Mention the types of T cells List the Types of T helper cell (CD4+) Discuss the Activation of T cells Define Interleukins Distinguish the Super Ag from ordinary Ag Show
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationCytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationCase 54. Cell-Mediated Immunity. Thought Questions. Basic Science Review and Discussion
Part_II-Gandhi 6/24/03 10:48 AM Page 161 HPI: IL is a 45-year-old diabetic man who had a kidney transplant 2 weeks ago. IL now presents with shortness of breath, severe hypertension, rapid weight gain,
More informationImmunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationASSESSMENT OF LYMPHOCYTE SUBGROUPS IN CHRONIC BRUCELLOSIS BEFORE AND AFTER IMMUNOTHERAPY
ASSESSMENT OF LYMPHOCYTE SUBGROUPS IN CHRONIC BRUCELLOSIS BEFORE AND AFTER IMMUNOTHERAPY D. Tahamzadeh 1, A. Massoud *1, G. Samar 2 and B. Nikbin 1 1) Department of Immunology, School of Medicine, Tehran
More informationNK cell flow cytometric assay In vivo DC viability and migration assay
NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with
More informationImmunosuppression for pediatric cardiac transplantation in the modern era
Ž. Progress in Pediatric Cardiology 11 2000 115 129 Immunosuppression for pediatric cardiac transplantation in the modern era Bill A. Pietra, Mark M. Boucek Department of Pediatrics, Uni ersity of Colorado
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationImmune system. Aims. Immune system. Lymphatic organs. Inflammation. Natural immune system. Adaptive immune system
Aims Immune system Lymphatic organs Inflammation Natural immune system Adaptive immune system Major histocompatibility complex (MHC) Disorders of the immune system 1 2 Immune system Lymphoid organs Immune
More informationJAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques
JAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques preferentially depletes NK Cells Ladawan Kowawisatsut 1 Kovit Pattanapanyasat 1 Aftab A. Ansari 2 1 Department of Immunology
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationImmunopharmacology: Immunosuppression in Organ Transplanation
Immunopharmacology: Immunosuppression in Organ Transplanation Prof D. A. Joyce Pharm 3320/3321 Organ Transplants, Australia Organ Donors (2013) Kidney 630 Liver 248 Heart 77 Lung 167 Pancreas 33 Bone Marrow
More informationMonocyte subsets in health and disease. Marion Frankenberger
Monocyte subsets in health and disease Marion Frankenberger main cellular components: Leukocytes Erythrocytes Composition of whole blood Monocytes belong to the cellular components of peripheral blood
More informationEstablishing a Pure Lymphocyte Gate for Subset Analysis by Flow Cytometry
Cytornetry (Communications in Clinical Cytometry) 26:172-177 (1996) Establishing a Pure Lymphocyte Gate for Subset nalysis by Flow Cytometry Joseph M. Homtinovich, Sara D. Sparks, and Karen P. Mann Clinical
More informationMycophenolate Mofetil, Microemulsion Cyclosporine, and Prednisone as Primary Immunosuppression for Pediatric Liver Transplant Recipients
Mycophenolate Mofetil, Microemulsion Cyclosporine, and Prednisone as Primary Immunosuppression for Pediatric Liver Transplant Recipients John F. Renz,* Jennifer Lightdale, Christine Mudge, Peter Bacchetti,
More informationProf. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology
By Prof. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology Lecture objectives: At the end of the lecture you should be able to: Enumerate features that characterize acquired immune response
More information3/6/2017. Treatment of Detected Antibodies. I have financial relationship(s) with: Thoratec/St. Jude/Abbott Consultant CareDx Consultant/Speaker
Treatment of Detected Antibodies Sean Pinney, MD Director, Advanced Heart Failure & Transplantation Mount Sinai Hospital New York, NY Sean Pinney, MD Associate Professor of Medicine Icahn School of Medicine
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationElevation of Antidonor Immunoglobulin M Levels Precedes Acute Lung Transplant Rejection
Elevation of Antidonor Immunoglobulin M Levels Precedes Acute Lung Transplant Rejection Kentaroh Miyoshi, MD, Yoshifumi Sano, MD, Masaomi Yamane, MD, Shinichi Toyooka, MD, Takahiro Oto, MD, and Shinichiro
More informationT cell development October 28, Dan Stetson
T cell development October 28, 2016 Dan Stetson stetson@uw.edu 441 Lecture #13 Slide 1 of 29 Three lectures on T cells (Chapters 8, 9) Part 1 (Today): T cell development in the thymus Chapter 8, pages
More informationThe g c Family of Cytokines Prof. Warren J. Leonard M.D.
The Family of Cytokines Chief, Laboratory of Molecular Immunology Director, Immunology Center National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services
More informationImmune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine
Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen
More informationCentral tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)
More informationMechanisms of Immune Tolerance
Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationImmunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency
Immunology Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency Transplant Immunology Transplantation is the process of moving cells, tissues or organs from one site to another
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationAljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department
More informationThe Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity
The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign
More informationImmunosuppressive therapy after human lung transplantation
Eur Respir J 2004; 23: 159 171 DOI: 10.1183/09031936.03.00039203 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 CONTRIBUTIONS FROM THE EUROPEAN
More informationThird line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!
Topic 8 Specific Immunity (adaptive) (18) Topics - 3 rd Line of Defense - B cells - T cells - Specific Immunities 1 3 rd Line = Prophylaxis via Immunization! (a) A painting of Edward Jenner depicts a cow
More informationMECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW
MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW YVON LEBRANCHU Service Néphrologie et Immunologie Clinique CHU TOURS ANTIGEN PRESENTING CELL CD4 + T CELL CYTOKINE PRODUCTION CLONAL
More informationTransplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
More informationThe Lymphatic System and Body Defenses
PowerPoint Lecture Slide Presentation by Patty Bostwick-Taylor, Florence-Darlington Technical College The Lymphatic System and Body Defenses 12PART B Adaptive Defense System: Third Line of Defense Immune
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationChapter 23 Immunity Exam Study Questions
Chapter 23 Immunity Exam Study Questions 1. Define 1) Immunity 2) Neutrophils 3) Macrophage 4) Epitopes 5) Interferon 6) Complement system 7) Histamine 8) Mast cells 9) Antigen 10) Antigens receptors 11)
More informationFoundations in Microbiology
Foundations in Microbiology Fifth Edition Talaro Chapter 15 The Acquisition of Specific Immunity and Its Applications Chapter 15 2 Chapter Overview 1. Development of the Dual Lymphocyte System 2. Entrance
More information15 Immunodeficiencies
15 Immunodeficiencies A. Acquired causes of immunodeficiencies 1. Environmental (UV irradiation) 2. Drug induced (immunosuppressants) 3. non-hiv Viral (measles virus) Dr. Andrea Hubbard School of Pharmacy
More informationNatural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri
Natural Killer Cells: Development, Diversity, November 26, 2008 The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA 1 Human
More informationAs outlined under External contributions (see appendix 7.1), the group of Prof. Gröne at the
3 RESULTS As outlined under External contributions (see appendix 7.1), the group of Prof. Gröne at the DKFZ in Heidelberg (Dept. of Cellular and Molecular pathology) contributed to this work by performing
More informationScottish Medicines Consortium
Scottish Medicines Consortium tacrolimus, 5mg/ml concentrate for infusion and 0.5mg, 1mg, 5mg hard capsules (Prograf ) No. (346/07) Astellas Pharma Ltd 12 January 2007 The Scottish Medicines Consortium
More information